Mar 08, 2013
Follow-up results from one of several groundbreaking gene therapy studies reported in 2008 in patients with an inherited form of retinal blindness confirmed the earlier positive results of substantial improvement in vision.
Feb 21, 2013
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.
Feb 14, 2013
As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention.
Feb 13, 2013
Big Data, the new groundbreaking, open access, peer-reviewed journal published by Mary Ann Liebert, Inc., publishers, will launch its inaugural issue at the Strata conference in Santa Clara, CA, February 26-28, 2013.
Feb 13, 2013
The fascinating Conclaves system for electing a new pope, which has been in place since the late 1200s is described in "Creating the Rules of the Modern Papal Election," published in Election Law Journal from Mary Ann Liebert, Inc., publishers.
Feb 11, 2013
Mary Ann Liebert, Inc., publishers is pleased to announce the appointment of Robert Lanza, MD as Editor-in-Chief of BioResearch Open Access effective immediately.
Feb 06, 2013
Mary Ann Liebert, Inc., publishers announces the preview issue of New Space, the only international peer-reviewed journal dedicated to space innovation and entrepreneurship.
Feb 01, 2013
Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases.
Jan 28, 2013
The U.S. Department of Agriculture (USDA) invests nearly $10 million a year to support about 250 nanoscale science and engineering projects that could lead to revolutionary advances in agriculture and food systems.
Jan 23, 2013
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells.